568 related articles for article (PubMed ID: 19451908)
1. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
Kesselheim AS
Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
[No Abstract] [Full Text] [Related]
2. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
Matheny J; Smith B; Courtney B; Mair M
Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
[No Abstract] [Full Text] [Related]
3. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
[TBL] [Abstract][Full Text] [Related]
4. Biodefense. Critics question proposed countermeasures agency.
Kaiser J
Science; 2005 Nov; 310(5749):755. PubMed ID: 16272086
[No Abstract] [Full Text] [Related]
5. Concerns raised over declining antiinfectives R&D.
Fox JL
Nat Biotechnol; 2003 Nov; 21(11):1255-6. PubMed ID: 14595340
[No Abstract] [Full Text] [Related]
6. Biodefense. House passes plan for drug, vaccine R&D.
Kaiser J
Science; 2006 Oct; 314(5796):39. PubMed ID: 17023625
[No Abstract] [Full Text] [Related]
7. FDA launches priority vouchers for neglected-disease drugs.
Waltz E
Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
[No Abstract] [Full Text] [Related]
8. A critical tipping point.
Zuckerman MB
US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
[No Abstract] [Full Text] [Related]
9. Developing drugs for developing countries.
Ridley DB; Grabowski HG; Moe JL
Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
[TBL] [Abstract][Full Text] [Related]
10. An uncertain call to arms.
Fraser CM
Science; 2004 Apr; 304(5669):359. PubMed ID: 15087509
[No Abstract] [Full Text] [Related]
11. In defence of priority review vouchers.
Sonderholm J
Bioethics; 2009 Sep; 23(7):413-20. PubMed ID: 19659848
[TBL] [Abstract][Full Text] [Related]
12. Drugs and vaccines for the common defense: refining FDA regulation to promote the availability of products to counter biological attacks.
Javitt GH
J Contemp Health Law Policy; 2002; 19(1):37-116. PubMed ID: 12733223
[No Abstract] [Full Text] [Related]
13. Determinants of vaccine supply.
Natl Bur Econ Res Bull Aging Health; 2011; (3):2-3. PubMed ID: 22207917
[No Abstract] [Full Text] [Related]
14. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
Lee VH
Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
[No Abstract] [Full Text] [Related]
15. The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.
Shani S; Yahalom Z
Food Drug Law J; 2008; 63(3):701-11. PubMed ID: 19031669
[No Abstract] [Full Text] [Related]
16. Readying for bioterrorism. Senators question nation's preparedness, propose big spending increase.
Lovern E
Mod Healthc; 2001 Oct; 31(41):9. PubMed ID: 11668841
[No Abstract] [Full Text] [Related]
17. Funding agendas: has bioterror defense been over-prioritized?
May T
Am J Bioeth; 2005; 5(4):34-44. PubMed ID: 16109694
[TBL] [Abstract][Full Text] [Related]
18. Bioterrorism defense education: prioritizing public health education.
Egan EA
Am J Bioeth; 2005; 5(4):47-8. PubMed ID: 16109696
[No Abstract] [Full Text] [Related]
19. Ganging up on the FDA.
Stone PH
Natl J (Wash); 1995 Feb; 27(7):410-4. PubMed ID: 10140321
[No Abstract] [Full Text] [Related]
20. FDA and EMEA pool scientific advice.
Katsnelson A
Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
[No Abstract] [Full Text] [Related]
[Next] [New Search]
